Evidence map›Paper›PMID 36261631›Full record

ReviewNature protocols2022

A microfluidic Braille valve platform for on-demand production, combinatorial screening and sorting of chemically distinct droplets.

Ramesh Utharala, Anna Grab, Vida Vafaizadeh, Nicolas Peschke, Martine Ballinger, Denes Turei, Nadine Tuechler, Wenwei Ma, Olga Ivanova, Alejandro Gil Ortiz and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ramesh Utharala *European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Anna Grab *European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Vida Vafaizadeh *European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0875-6246
Nicolas PeschkeEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Martine BallingerEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Denes TureiEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Nadine TuechlerEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8125-3098
Wenwei MaEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Olga IvanovaFaculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Heidelberg, Germany.
Alejandro Gil OrtizEuropean Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Julio Saez-RodriguezFaculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8552-8976
Christoph A MertenInstitute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. christoph.merten@epfl.ch.ORCID http://orcid.org/0000-0001-8790-4659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Droplet microfluidics is a powerful tool for a variety of biological applications including single-cell genetics, antibody discovery and directed evolution. All these applications make use of genetic libraries, illustrating the difficulty of generating chemically distinct droplets for screening applications. This protocol describes our Braille Display valving platform for on-demand generation of droplets with different chemical contents (16 different reagents and combinations thereof), as well as sorting droplets with different chemical properties, on the basis of fluorescence signals. The Braille Display platform is compact, versatile and cost efficient (only ~US$1,000 on top of a standard droplet microfluidics setup). The procedure includes manufacturing of microfluidic chips, assembly of custom hardware, co-encapsulation of cells and drugs into droplets, fluorescence detection of readout signals and data analysis using shared, freely available LabVIEW and Python packages. As a first application, we demonstrate the complete workflow for screening cancer cell drug sensitivities toward 74 conditions. Furthermore, we describe here an assay enabling the normalization of the observed drug sensitivity to the number of cancer cells per droplet, which additionally increases the robustness of the system. As a second application, we also demonstrate the sorting of droplets according to enzymatic activity. The drug screening application can be completed within 2 d; droplet sorting takes ~1 d; and all preparatory steps for manufacturing molds, chips and setting up the Braille controller can be accomplished within 1 week.

Indexed as

Biological AssayMicrofluidicsCell Movement

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.